HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Antibody-based cancer therapeutics represent a promising frontier in the fight against cancer. These therapies harness the specificity of antibodies to target cancer cells with precision, minimizing damage to healthy tissues. By leveraging the body's immune system, these treatments aim to enhance the natural defenses against cancer.
Monoclonal antibodies, a key component of this therapeutic approach, are designed to recognize and bind to specific proteins expressed on the surface of cancer cells. This targeted binding can interfere with the cancer cell's ability to grow and divide, ultimately leading to cell death.
The development of antibody-drug conjugates is another avenue in antibody-based cancer therapy. In this approach, antibodies are coupled with potent cytotoxic drugs. Once the antibody binds to the cancer cell, it delivers the drug directly to the site of action, maximizing the therapeutic effect while minimizing systemic exposure.
Immunotherapies, including immune checkpoint inhibitors, fall under the umbrella of antibody-based cancer therapeutics. These therapies work by releasing the brakes on the immune system, allowing it to recognize and attack cancer cells more effectively. This approach has shown remarkable success in certain cancers, leading to durable responses in some patients.
Despite these advancements, challenges remain, including the identification of suitable target antigens and potential resistance mechanisms. Ongoing research aims to address these challenges, pushing the boundaries of antibody-based cancer therapeutics and expanding their applicability across various cancer types.
